New combo attack on tough liver cancer
NCT ID NCT07363512
Summary
This study is testing whether combining radiation therapy with two drugs (tislelizumab and anlotinib) can help control advanced liver cancer that has spread into a major vein. It aims to shrink tumors, stop their growth, and potentially make surgery an option for some patients. The trial will enroll 27 adults with this specific form of liver cancer who have not had prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.